• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

FDA actions in brief

News
Article

Pregabalin (Lyrica, Pfizer) was granted an expanded indication to include the adjunctive treatment of partial onset seizures in adults with epilepsy.

Pregabalin (Lyrica, Pfizer) was granted an expanded indication to include the adjunctive treatment of partial onset seizures in adults with epilepsy.

Sildenafil (Revatio, Pfizer) was approved for the treatment of pulmonary arterial hypertension (PAH).

FDA approved meropenem 500 mg IV (Merrem IV, AstraZeneca) for the treatment of complicated skin and skin structure infections (cSSSIs).

Azithromycin extended release (Zmax, Pfizer) was approved for single-dose treatment of mild-to-moderate acute bacterial sinusitis (ABS) and community-acquired pneumonia (CAP) in adults.

Tetanus toxoid and reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Adacel, sanofi pasteur) was approved for protection against tetanus, diphtheria, and pertussis in patients aged 11 to 64 years.

FDA approved insulin detemir (rDNA origin) injection (Levemir, Novo Nordisk) for the treatment of diabetes. The long-acting basal human insulin analogue has a relatively flat action profile and prolonged duration of action of up to 24 hours.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.